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Abstract
Until  recently,  few  molecular  aberrations
were recognized in T-cell acute lymphoblastic
leukemia (T-ALL) and they were restricted to
aberrations  involving  the  T-cell  receptor
(TCR). The introduction of powerful technolo-
gies has allowed to identify novel rearrange-
ments. In this context, we have performed a
gene expression profiling analysis on a rela-
tively  large  cohort  (n=69)  of  adult  patients
with  a  diagnosis  of  T-ALL.  By  unsupervised
clustering,  we  identified  5  subgroups.  Of
these, one branch included 7 patients (10%)
whose gene expression profile resembled that
of AML. These cases were characterized by the
overexpression  of  a  large  set  of  myeloid-re-
lated  genes,  as  well  as  of  miR-223.  Finally,
these patients appear to have an unfavorable
clinical course. This newly identified subset of
T-ALL cases partly resembles the so-called ETP
(early  T-precursor)  pediatric  subgroup:  both
age groups have in fact a peculiar gene expres-
sion profile, an unfavorable outcome and an
incidence of about 10%.
T-cell acute lymphoblastic leukemia (T-ALL)
is a malignancy of T-cell precursors, present in
about 15% of children and 25% of adults. Up to
the past decade, few events were recognized in
T-ALL, with biologic knowledge being generally
restricted to aberrations involving the T-cell re-
ceptor (TCR). The scenario has been recently
rapidly evolving: the most common aberrations
currently include i) overexpression of known
ongogenes, such as TLX1 and TLX3; ii) muta-
tions  of  NOTCH1,  FBXW7,  JAK1,  WT1  and
PTEN; iii) rearrangements, that include SIL/TAL1,
NUP214/ABL1,  EML/ABL1,  CALM/AF10  and
TAF_I-NUP214; iv) finally, amplifications and
deletions have been documented, the most fre-
quent involving MYB, CDKN2A and RB1.
The identification of these aberrations has
led  to  pinpoint  cellular  functions  that  are
specifically deregulated, such as cell cycle con-
trol,  cell  differentiation,  proliferation  and/or
survival  and  self-renewal  properties.  In  this
context, gene expression analysis has proven
useful in recognizing signatures that are asso-
ciated with the overexpression of known onco-
genes,  with  the  differentiative  stage  of  the
leukemic  cell,  with  the  recognition  of  novel
subgroups, as well as with outcome.
A  broad  use  of  gene  expression  profiling
(GEP) has also permitted to identify distinct
subsets of patients and to recognize similari-
ties between different subsets and/or diseases.
In acute myeloid leukemia (AML), a subset of
cases whose genomic profile is similar to that
of CEBPA mutated patients was previously de-
scribed: these patients have a peculiar profile
that is characterized by the overexpression of
a set of T-lineage genes, NOTCH1 mutations
and hypermethylation of the CEBPA promoter,
suggesting that the combination of these le-
sions may lead to a mixed T-lineage/myeloid
lineage scenario.
By analyzing the gene expression profile of
69 samples of newly diagnosed adult T-ALL, we
have  identified,  by  unsupervised  analysis,  5
distinct  subgroups:  for  the  majority  of  them
the  underlying  lesion  had  been  previously
identified. In addition, we identified a novel
subgroup, defined myeloid-like, that revealed a
very peculiar profile and was characterized by
the overexpression of several myeloid-related
genes,  such  as  genes  codifying  for  myeloid
antigens,  myeloid  transcription  factors  (in-
cluding CEBPA) and granule proteins. These
cases were also characterized by high expres-
sion levels of IL-8. Notably, an unsupervised
clustering carried out in a series of cases that
included also 19 AML samples branched these
cases with the AML patients, corroborating the
strict similarity between the two subsets of pa-
tients. Interestingly, these cases did not have
peculiar  features  at  the  immunophenotypic
level.  Quantitative  PCR  experiments  con-
firmed the high expression levels of a set of
these genes, such as CEBPA, CEBPB, MPO and
IL-8, the latter being previously reported to be
associated  with  refractoriness  to  induction
chemotherapy.  Thus,  in  order  to  understand
the underlying mechanism responsible for this
characteristic signature and taking advantage
of the evidence that in AML hypermethylation
of the CEBPA promoter region appears respon-
sible of the mixed T-lineage/myeloid lineage,
we wondered if CEBPA methylation could play
a role also in our T-ALL series: we evaluated
the  CEBPA  promoter-CpG  island  methylation
status in 7 classic T-ALL cases and in 4 myeloid-
like patients. Our analysis revealed that only
1/7 T-ALL samples was methylated, while 2/4
myeloid-like patients were methylated despite
the high levels of CEBPA expression, thus indi-
cating  that  CEBPA  expression  levels  are  not
correlated  with  the  methylation  status  of  its
promoter  and  that  other  mechanisms  might
regulate CEBPA expression in T-ALL.
Considering that miR-223 regulates myeloid
differentiation, we subsequently evaluated the
expression of this miR: this analysis was car-
ried out on 5 myeloid-like patients, 12 T-ALL
patients, 8 AML patients and 3 CD2+ samples
obtained from healthy donors. The results ob-
tained  showed  that  “myeloid-like  patients”
have expression levels of miR-223 comparable
to those of AML and significantly higher than
those of the other T-ALL.
Finally,  we  evaluated  the  clinico-biologic
features of these patients: there was not a spe-
cific  differentiative  block  in  these  cases,  as
well as no peculiar immunophenotypic charac-
teristic; similarly, the clinical presentation was
not different from that of the remaining T-ALL
cases. At variance, the outcome of these pa-
tients was poor: in fact, of the 7 patients 2 suc-
cumbed  during  induction  chemotherapy,  2
were refractory to induction chemotherapy and
only 2 obtained a complete remission, with 1
patient relapsing shortly after.
The “myeloid-like” group in some way re-
sembles the ETP (early T-precursor) subgroup
recently identified in pediatric T-ALL. In fact: i)
the  incidence  of  myeloid-like  and  ETP  is  of
10% and 12% of cases in adult and pediatric co-
horts, respectively; ii) both groups retain a cer-
tain degree of multilineage differentiation po-
tential; iii) both cohorts have been associated
to an unfavorable clinical outcome.
In conclusion, this work allowed to define a
novel subgroup of adult T-ALL that was not rec-
ognized by other standard approaches, under-
lining the importance of gene profiling in fur-
ther dissecting acute leukemia subsets. The
recognition  of  this  subgroup  may  also  have
clinical,  prognostic  and  therapeutic  implica-
tions, since the outcome of this set of patients
appears to be particularly poor, and suggests
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